Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Inclusion criteria * Adult patients with SPMS as per the treating physician's clinical assessment (Therapeutic Goods Administration \[TGA\]-approved indication of Mayzent). * Expanded Disability Status Scale (EDSS) of 3.0 to 6.5 (inclusive). * Patients accessing Mayzent via the Mayzent Experience Program (MEP) must have met the MEP criteria, and if available, the Pharmaceutical Benefits Scheme (PBS) restrictions recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). * Patients accessing Mayzent via the PBS must have met the PBS restrictions. Exclusion criteria * Patients who were contraindicated for Mayzent treatment according to the TGA-approved Product Information. * Patients diagnosed with clinically isolated syndrome or primary progressive multiple sclerosis (MS).